Patriot Financial Group Insurance Agency LLC Sells 175 Shares of Eli Lilly and Company (NYSE:LLY)

Patriot Financial Group Insurance Agency LLC decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 7.9% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,027 shares of the company’s stock after selling 175 shares during the quarter. Patriot Financial Group Insurance Agency LLC’s holdings in Eli Lilly and Company were worth $1,836,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Tidemark LLC bought a new stake in Eli Lilly and Company during the fourth quarter worth about $29,000. Core Wealth Advisors Inc. boosted its position in shares of Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after acquiring an additional 32 shares in the last quarter. Lynx Investment Advisory bought a new position in Eli Lilly and Company in the second quarter valued at approximately $32,000. Frank Rimerman Advisors LLC acquired a new position in Eli Lilly and Company during the fourth quarter valued at approximately $37,000. Finally, St. Johns Investment Management Company LLC lifted its stake in Eli Lilly and Company by 123.3% during the fourth quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock worth $39,000 after purchasing an additional 37 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 22,206 shares of the business’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $822.11, for a total value of $18,255,774.66. Following the transaction, the insider now directly owns 98,401,604 shares of the company’s stock, valued at $80,896,942,664.44. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the transaction, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 22,206 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $822.11, for a total value of $18,255,774.66. Following the completion of the sale, the insider now directly owns 98,401,604 shares of the company’s stock, valued at approximately $80,896,942,664.44. The disclosure for this sale can be found here. Insiders have sold a total of 1,120,089 shares of company stock worth $990,278,343 in the last 90 days. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Down 0.6 %

LLY stock traded down $6.12 during midday trading on Wednesday, hitting $948.36. The stock had a trading volume of 629,821 shares, compared to its average volume of 3,074,808. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The firm has a market cap of $901.33 billion, a P/E ratio of 140.80, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41. The business has a fifty day moving average price of $887.63 and a two-hundred day moving average price of $816.72. Eli Lilly and Company has a 1-year low of $516.57 and a 1-year high of $972.53.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.55%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is 76.58%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on LLY shares. Berenberg Bank boosted their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Deutsche Bank Aktiengesellschaft upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and upped their price objective for the stock from $725.00 to $1,025.00 in a research report on Monday, August 12th. Truist Financial restated a “buy” rating and issued a $1,000.00 target price (up previously from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Argus upped their price target on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a report on Tuesday, May 14th. Finally, Bank of America raised their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a report on Friday, August 9th. Two analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $961.76.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.